We estimate that the CEO of Zymeworks Inc. ($ZYME), Kenneth Galbraith, received a compensation of $6,613,180 in 2025. This is an increase of 16.95% from an estimated $5,492,157 in 2024.
These estimates are based on a new DEF14A filing, filed with the SEC on October 26, 2026. Note that parsing errors may occur.
You can track $ZYME on Quiver Quantitative's $ZYME stock dashboard.
$ZYME Stock Insider Trading Activity
$ZYME Stock insiders have traded $ZYME stock on the open market 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $ZYME stock by insiders over the last 6 months:
- ADAM SCHAYOWITZ (EVP, Head of R&D) sold 13,832 shares for an estimated $357,557
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$ZYME Stock Hedge Fund Activity
We have seen 86 institutional investors add shares of $ZYME Stock stock to their portfolio, and 95 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- NOMURA ASSET MANAGEMENT INTERNATIONAL INC. added 889,802 shares (+inf%) to their portfolio in Q2 2026, for an estimated $23,259,424
- PERCEPTIVE ADVISORS LLC added 672,875 shares (+19.2%) to their portfolio in Q2 2026, for an estimated $17,588,952
- MPM BIOIMPACT LLC removed 565,249 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $14,775,608
- NUVEEN, LLC removed 532,273 shares (-81.7%) from their portfolio in Q2 2026, for an estimated $13,913,616
- DEUTSCHE BANK AG\ removed 524,060 shares (-56.9%) from their portfolio in Q2 2026, for an estimated $13,698,928
- CAPRICORN FUND MANAGERS LTD removed 520,681 shares (-51.7%) from their portfolio in Q2 2026, for an estimated $13,610,601
- FIRST TRUST ADVISORS LP added 340,363 shares (+inf%) to their portfolio in Q2 2026, for an estimated $8,897,088
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$ZYME Stock Price Targets
Multiple analysts have issued price targets for $ZYME recently. We have seen 3 analysts offer price targets for $ZYME in the last 6 months, with a median target of $37.0.
Here are some recent targets:
- Gregory Renza from Truist Securities set a target price of $31.0 on 07/07/2026
- Eva Fortea Verdejo from Wells Fargo set a target price of $37.0 on 06/30/2026
- Robert Burns from HC Wainwright & Co. set a target price of $46.0 on 06/03/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
